国际口腔医学杂志
國際口腔醫學雜誌
국제구강의학잡지
JOURNAL OF INTERNATIONAL STOMATOLOGY
2014年
2期
133-136
,共4页
王涛%廖天安%王鸿%邓伟%于大海
王濤%廖天安%王鴻%鄧偉%于大海
왕도%료천안%왕홍%산위%우대해
骨髓间充质干细胞%血管内皮生长因子%放射损伤
骨髓間充質榦細胞%血管內皮生長因子%放射損傷
골수간충질간세포%혈관내피생장인자%방사손상
bone mesenchymal stem cell%vascular endothelial growth factor%irradiated injury
目的:采用血管内皮生长因子(VEGF)基因修饰骨髓间充质干细胞(BMSC),观察其是否能改善放射治疗损伤区组织的生长情况。方法以60Coγ射线照射大鼠右后肢,在照射结束后第1天,将VEGF165基因修饰的BMSC注射至照射区肌肉组织细胞,共注射2次,间隔2周,治疗结束后行检测VEGF165 mRNA、VEGF蛋白含量,并观察其血管神经的显微结构。结果注射VEGF165基因修饰的BMSC治疗后,照射区组织中的VEGF165 mRNA及VEGF蛋白的表达均明显增高,血管、神经超微结构基本恢复正常。结论 VEGF165基因修饰的BMSC能有效修复肌肉组织的放射损伤,为临床治疗提供了一定的实验基础。
目的:採用血管內皮生長因子(VEGF)基因脩飾骨髓間充質榦細胞(BMSC),觀察其是否能改善放射治療損傷區組織的生長情況。方法以60Coγ射線照射大鼠右後肢,在照射結束後第1天,將VEGF165基因脩飾的BMSC註射至照射區肌肉組織細胞,共註射2次,間隔2週,治療結束後行檢測VEGF165 mRNA、VEGF蛋白含量,併觀察其血管神經的顯微結構。結果註射VEGF165基因脩飾的BMSC治療後,照射區組織中的VEGF165 mRNA及VEGF蛋白的錶達均明顯增高,血管、神經超微結構基本恢複正常。結論 VEGF165基因脩飾的BMSC能有效脩複肌肉組織的放射損傷,為臨床治療提供瞭一定的實驗基礎。
목적:채용혈관내피생장인자(VEGF)기인수식골수간충질간세포(BMSC),관찰기시부능개선방사치료손상구조직적생장정황。방법이60Coγ사선조사대서우후지,재조사결속후제1천,장VEGF165기인수식적BMSC주사지조사구기육조직세포,공주사2차,간격2주,치료결속후행검측VEGF165 mRNA、VEGF단백함량,병관찰기혈관신경적현미결구。결과주사VEGF165기인수식적BMSC치료후,조사구조직중적VEGF165 mRNA급VEGF단백적표체균명현증고,혈관、신경초미결구기본회복정상。결론 VEGF165기인수식적BMSC능유효수복기육조직적방사손상,위림상치료제공료일정적실험기출。
Objective This study aimed to resume the ability of revascularization of the irradiated tissue by implantation of vascular endothelial growth factor(VEGF)-modified bone mesenchymal stromal cell(BMSC). Methods Each mouse was irradiated with 60Coγray on their right leg. The irradiated muscular tissues of the animal models were injected with VEGF165-modified BMSCs, and a second dose was administered after two weeks. We determined the expression of VEGF165 mRNA, VEGF165 protein, and ultrastructure of the vessels and nerves after gene therapy. Results VEGF165 mRNA and VEGF165 protein had high levels of expression in the irradiated tissue after the injection of VEGF165 -modified BMSCs. The configuration and ultrastructure of the vessels and nerves returned to normal. Conclusion VEGF165-modified BMSCs can resume the ability of the vessels and nerves of an irradiated tissue. This study provides abasis for the clinical application of VEGF165-modified BMSCs.